Study guide
11.2 Labeling & Packaging of Dispensed Drugs
Minnesota MPJE Pharmacy Jurisprudence
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 About the Minnesota MPJE 1.2 NABP Competency Areas & Weights 1.3 How to Use This Guide & Study Strategy
2 Federal Controlled Substances Foundations
2.1 CSA Schedules I–V & MN Alignment 2.2 DEA Registration, Forms 222/106/41 & Security 2.3 Federal CS Prescription Rules (CII–CV) 2.4 Inventories, Recordkeeping & Theft/Loss
3 Federal Drug Regulation, Privacy & Supply Chain
3.1 FD&C Act, Legend vs OTC, Misbranding & Adulteration 3.2 OBRA '90, Medicaid DUR & Federal Counseling Floor 3.3 HIPAA Privacy for Pharmacy 3.4 DSCSA & Drug Supply Chain Integrity
4 MN Board, Licensure & Eligibility
4.1 Minnesota Board of Pharmacy Authority & Sources of Law 4.2 Pharmacist Licensure by Exam & Score Transfer 4.3 License Transfer (Reciprocity) & Background Checks 4.4 Interns, Preceptors & 1,600-Hour Experience
5 Renewal, CE, PIC & Discipline
5.1 License Renewal & 30-Hour Biennial CE 5.2 Pharmacist-in-Charge Duties 5.3 Discipline & Unprofessional Conduct 5.4 HPSP, Impaired Practitioners & Mandatory Reporting
6 Technicians, Interns & Supervision
6.1 Technician Registration, Training & CE 6.2 Supervision Ratios (Statute 151.102 & Rule 6800.3850) 6.3 Intern Scope, Delegation & Certification of Accuracy
7 Prescription Authority & Validity
7.1 Who May Prescribe in Minnesota 7.2 Prescription Content & Validity Requirements 7.3 Controlled Substance Prescribing (Chapter 152 + Federal) 7.4 Refills, Partial Fills & Quantity Limits
8 Advanced MN Pharmacist Practice
8.1 Collaborative Practice Agreements & Medication Therapy Management 8.2 Pharmacist Prescriptive Authority (Minn. Stat. 151.37) 8.3 Immunizations & Vaccine Administration 8.4 Drug Administration & Therapy Management
9 Counseling, DUR & Patient Safety
9.1 Patient Counseling Requirements (Rule 6800.0910) 9.2 Prospective Drug Utilization Review 9.3 Returning & Reusing Drugs (Rule 6800.2700)
10 MN PMP & Opioid Public-Health Laws
10.1 Minnesota PMP Overview, Reporting & Pharmacist Use 10.2 Naloxone Access, Steve’s Law & Opioid Antagonists 10.3 Legitimate Medical Purpose & Red Flags
11 Dispensing: Transfers, Labels & Substitution
11.1 Prescription Transfers Between Pharmacies 11.2 Labeling & Packaging of Dispensed Drugs 11.3 Generic Substitution & Product Selection 11.4 Emergency Dispensing, OTC/BTC & Pseudoephedrine
12 Pharmacy Operations & Facilities
12.1 Pharmacy Permits, Classifications & Inspections 12.2 Security, Delivery & Work Conditions 12.3 Operational Recordkeeping & Inventories 12.4 Central Fill, Centralized Processing & Automation
13 Compounding & Hazardous Drugs
13.1 Sterile, Nonsterile & Hazardous Compounding 13.2 Minnesota Compounding Rules & Beyond-Use Dates
14 Test-Day Strategy & Final Review
14.1 When Minnesota Law Is Stricter Than Federal Law 14.2 Test-Day Strategy & Common Traps
11.2 Labeling & Packaging of Dispensed Drugs
Key Takeaways Explain This Topic AI
Rule 6800.3400 requires outpatient labels to include pharmacy identity/phone, patient, Rx number, prescriber, directions, manufacturer/distributor of the finished dosage form, drug name/strength, date of issue or renewal, auxiliary labels, and (for most legend/non-original OTC) a physical description/ID code
Central-service fills use the dispensing pharmacy’s name/address/phone on the patient label and must carry a central-service identifier
Rule 6800.4150 adds driving/alcohol caution for systemically administered CS (and other pharmacist-judged drugs) and the federal “do not transfer” CS caution; Minn. Stat. §151.212 requires an opioid overdose/addiction caution on outpatient opiate labels
Federal PPPA (CPSC) child-resistant packaging applies to most oral prescription drugs unless a lawful patient or prescriber non-CRC request is documented
§151.212 also requires manufacturer/distributor on the immediate container label and accessible-label duties (large print/Braille/other Access Board methods) for patients who need them
Last updated: July 2026
11.2 Labeling & Packaging of Dispensed Drugs
Quick Answer: Under Rule 6800.3400 , drugs dispensed to outpatients (other than hospital inpatients, and excluding radiopharmaceuticals under a separate part) must be labeled with pharmacy name/address/phone, patient name, prescription number, prescriber name, directions, manufacturer or distributor of the finished dosage form , drug name and strength, date of original issue or renewal, auxiliary labels as needed, and—after July 1, 2008—a physical description/ID code for legend drugs and non-original-container nonlegend drugs. Rule 6800.4150 and Minn. Stat. §151.212 add controlled-substance and opioid caution statements. Packaging must meet federal PPPA child-resistant requirements unless a lawful exemption applies.
Labeling is Area 3 competency 3.5; packaging is 3.6. Exam items often hide a missing element (manufacturer, physical description, opioid caution) inside an otherwise perfect vignette.
Outpatient Label Elements — Rule 6800.3400, Subp. 1
Except for radiopharmaceuticals, all drugs dispensed to or for a patient other than a hospital inpatient must include:
Element Notes
A. Pharmacy name, address, telephone Central service pharmacies use the identity of the pharmacy dispensing to the patient
- B. Patient’s name Individual patient
- C. Prescription number Unique Rx ID
- D. Prescribing practitioner name Lawful prescriber
- E. Directions for use Counseling and use baseline
- F. Manufacturer or distributor of the finished dosage form Matches §151.212 statutory duty
G. Auxiliary labels as needed Clinical warnings, storage, etc.
H. Date of original issue or renewal Freshness of the fill event
I. Generic or trade name and strength Unless prescriber specifies contrary; special rules for combinations/compounds
J. Central-service identifier when filled as part of a central service operation Shows which facility filled
K. Physical description / ID code Required after July 1, 2008 for legend drugs and nonlegend drugs not in manufacturer’s original container (investigational study exception)
Small containers and med packs
Subp. 2: If the immediate container is too small for full labeling, a partial label with at least patient name and Rx number may go on the container, with complete labeling on an appropriate outer container .
Subp. 3: With consent of the patient, caregiver, or prescriber, a pharmacist may use a customized patient medication package meeting USP standards (rule cites USP chapter standards for med packs).
Subp. 4–5: Veterinary labels add species, owner/facility identifiers, withdrawal times for food animals, and related items; radiopharmaceuticals follow 6800.8550 .
Statutory Overlay — Minn. Stat. §151.212
Subdivision 1 requires a label permanently affixed to the immediate container received by the purchaser, bearing the manufacturer or distributor of the finished dosage form and all other information required by law and board rules.
Subdivision 2 (controlled substances / impairing drugs):
Board rules must require notice when a CS (or other board-designated drug) alone or with alcohol may impair driving —implemented in practice by Rule 6800.4150 .
Whenever a prescription drug containing an opiate is dispensed for outpatient use , the label must prominently state: “Caution: Opioid. Risk of overdose and addiction.”
Subdivision 4 (accessible labels): Pharmacies must make reasonable efforts to inform the public (and known vision-impaired patients) that accessible container labels (large print, Braille, or other U.S. Access Board best-practice methods) are available at no additional cost on request, with capacity expectations phased so that by January 1, 2026 all pharmacies must be able to provide them timely (correctional-institution dispensing excluded).
Controlled-Substance Caution Labels — Rule 6800.4150
Drugs administered systemically as controlled substances under chapter 152 (and board CS parts), and other drugs the pharmacist judges appropriate, when dispensed to or for an adult outpatient (not hospital or nursing-home inpatient), must meet 6800.3400 and also bear:
“Caution: Taking this drug alone or with alcohol may impair your ability to drive.”
Controlled substances must also bear:
“Caution: Federal law prohibits the transfer of this drug to any person other than the patient for whom it was prescribed.”
Stack this with the §151.212 opioid sentence when the product is an outpatient opiate. Missing any of these cautions is a classic labeling miss.
Packaging: Federal PPPA Child-Resistant Containers
The federal Poison Prevention Packaging Act (PPPA) , enforced by the CPSC , requires special (child-resistant) packaging for most oral prescription drugs for household use. Minnesota practice must comply with that federal packaging floor:
Default: dispense in child-resistant containers
Patient may request non-child-resistant packaging (often a blanket or per-prescription request—document the request)
- Prescriber may request non-CRC for a particular prescription
- Manufacturer unit-of-use that is already CRC-compliant may be dispensed as packaged when appropriate
Do not invent Minnesota “CRC is optional for everyone over 65” shortcuts—age alone is not an automatic waiver. Institutional unit-dose systems and certain exempted products follow federal exemptions, not pharmacy convenience.
Beyond-Use Dating and Auxiliary Warnings (Practice Integration)
Rule 6800.3400 does not replace USP or Minnesota compounding BUD rules for compounded preparations (covered in the compounding chapter). For ordinary manufactured products, follow manufacturer dating, stability, and board expectations; use auxiliary labels for refrigeration, shake-well, take-with-food, photosensitivity, and similar high-risk use points. Physical description (tablet color/shape/imprint) is a patient-safety identification control, not decoration.
Common Exam Traps
- Trap Fix
- Omitting manufacturer/distributor of finished dosage form Required by both rule and §151.212
- Skipping physical description on a count-and-pour legend drug Required under 6800.3400.1.K
- Using central-fill pharmacy identity instead of the dispensing pharmacy’s contact info Subp. 1.A
- Forgetting opioid caution on outpatient opiates §151.212, subd. 2(b)
- Treating CS transfer caution as optional 6800.4150
Dispensing oral Rx drugs in easy-open vials for every senior without request Document patient/prescriber non-CRC request
Study Checklist
Recite the 6800.3400 outpatient checklist including manufacturer and physical description.
Add 6800.4150 dual CS cautions and the §151.212 opioid sentence.
Explain central-service labeling and small-container outer-label rules.
Apply PPPA CRC defaults and documented exceptions.
Know accessible label duties under §151.212, subd. 4 .
If the label is incomplete, the dispense is incomplete—even when the clinical choice of drug was perfect.